NetworkNewsBreaks

FridaySep 11, 2026 9:20 am

NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) announced its placement in a BioMedWire editorial examining the potential of Lucid-MS to address limitations of existing multiple sclerosis (“MS”) treatments. The editorial highlights Quantum BioPharma’s U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed to protect and potentially rebuild the myelin sheath rather than suppress the immune system. According to the publication, the trial would mark the first time a drug based on this mechanism is tested in people…

Continue Reading

FridaySep 11, 2026 9:10 am

NetworkNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Names John Tattory Interim CFO Following Tom Fitzgerald Retirement

TransCode Therapeutics (NASDAQ: RNAZ) a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the retirement of Chief Financial Officer Tom Fitzgerald, who has served in the role since July 2018 and will resign as CFO and a director effective immediately while continuing to provide transition services. The company named John Tattory interim CFO, effective immediately. Tattory has more than 25 years of financial and operational management and leadership experience across pharmaceutical, medical device and biotechnology companies, including roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics and Windtree Therapeutics.…

Continue Reading

ThursdaySep 10, 2026 1:06 pm

NetworkNewsBreaks – AmpliTech Group, Inc. (NASDAQ: AMPG, AMPGZ) Receives $7.3 Million in Follow-On Orders for Asian 5G O-RAN Deployment 

AmpliTech Group (NASDAQ: AMPG, AMPGZ) received approximately $7.3 million in follow-on orders supporting deployments for an Asian mobile network operator (“MNO”) under its previously announced 5G O-RAN radio Letter of Intent (“LOI”) program. The orders follow deployment of AmpliTech O-RAN radios at end-customer 5G sites and represent renewed purchasing activity under the program. The company said the orders, together with recently received follow-on orders supporting its North American MNO program, restore momentum under the LOI program and support its efforts to convert its opportunity pipeline into shipments and revenue. To view the full press release, visit https://nnw.fm/IPa6Z About AmpliTech Group, Inc. AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGZ)…

Continue Reading

ThursdaySep 10, 2026 1:00 pm

NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development

VERAXA Biotech (NASDAQ: VRXA) recently appointed antibody therapeutics specialist Dr. Christoph Erkel as its chief scientific officer, taking responsibility for advancing the company’s proprietary BiTAC(R) technology and broader oncology pipeline toward clinical development. The company’s lead BiTAC-TCE program uses a conditionally active, dual-targeting approach designed to selectively activate T cells against cancer cells while potentially limiting effects on healthy tissue. Recent scientific advice from Germany’s Paul-Ehrlich-Institute provided additional clarity around the program’s proposed non-clinical development strategy, while preclinical data presented at the AACR Annual Meeting showed selective activity against cells expressing both target molecules. Beyond BiTAC, VERAXA is developing bispecific antibody-drug…

Continue Reading

ThursdaySep 10, 2026 12:36 pm

NetworkNewsBreaks – Silver Bow Mining Corp. (NYSE American: SBMT) Receives Bankruptcy Court Approval, Completes Initial Closing for Jefferson County Metallurgical Complex 

Silver Bow Mining (NYSE American: SBMT) announced that the U.S. Bankruptcy Court for the District of Montana approved the sale of specified Montana Tunnels Mining assets comprising the Jefferson County Metallurgical Complex to Silver Bow and its wholly owned subsidiary, Silver Bow Tunnels Corp. The company also completed the initial closing under its previously announced definitive asset purchase agreement after funding approximately $28.58 million into escrow to satisfy specified creditor obligations, including approximately $4.27 million owed to Jefferson County and $20.78 million in specified obligations to the Montana Department of Environmental Quality. The initial closing does not transfer ownership of the Complex to Silver Bow. The company…

Continue Reading

ThursdaySep 10, 2026 12:24 pm

NetworkNewsBreaks – Perpetuals.com Ltd. (NASDAQ: PDC) Launches Joint AI Trading Research Group with European Institute of Management 

Perpetuals.com (NASDAQ: PDC) and the European Institute of Management (“EIM”) launched a joint research group pairing more than 20 doctoral researchers with Perpetuals to develop AI-powered trading models combining machine learning and crowd intelligence. The researchers will have access to Perpetuals proprietary trading datasets and live venue data, with work focused on behavioral finance, trader performance classification, market microstructure and model risk. The initiative is expected to run for at least three years, with more than half of the participating researchers currently employed by Perpetuals. To view the full press release, visit https://nnw.fm/4uWPB About Perpetuals Perpetuals.com Ltd (NASDAQ: PDC) is a fintech company developing…

Continue Reading

ThursdaySep 10, 2026 12:14 pm

NetworkNewsBreaks – Earth Science Tech Inc.’s (ETST) B2B-B2C Healthcare Platform Powers Continued Revenue Growth

Earth Science Tech (OTC: ETST) is positioning itself as a vertically integrated healthcare company through its subsidiaries RxCompoundStore, Mister Meds, and Peaks Curative, combining compounding pharmacy, telemedicine, clinical support, and fulfillment capabilities. Its B2B and B2C business model allows the company to serve independent clinics while also selling customized medications directly to consumers, creating diversified revenue streams across physical and digital healthcare operations. In FY2026, ETST reported revenue of $35.7 million, up from $33.1 million in FY2025 and $11.95 million in FY2024, while also reporting positive operating cash flow and a stronger balance sheet. The company reduced total liabilities from $3.146…

Continue Reading

ThursdaySep 10, 2026 10:20 am

NetworkNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 2 Psilocybin Trial for Major Depressive Disorder

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (“MDD”) in the first half of 2027, with dosing expected to be completed by year-end. The Health Canada-authorized trial will enroll up to 200 participants across multiple Canadian sites and evaluate the safety and efficacy of a single supervised dose of Optimi naturally derived psilocybin, manufactured at its GMP facility. The company will exclusively own the trial results and plans…

Continue Reading

ThursdaySep 10, 2026 10:10 am

NetworkNewsBreaks – SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Launches Overwatch Patrol for GPS-Denied Dismounted Operations

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) launched Overwatch Patrol, a dismounted positioning application designed to provide continuous location information to soldiers and security personnel when GPS is jammed, spoofed, degraded or unavailable. Unveiled at the International Defense Industry Exhibition (“MSPO”) in Kielce, Poland, Overwatch Patrol operates through the company’s cloud-based Overwatch Positioning Network without additional hardware and can be delivered through a native application or standard web browser. The platform enables multiple team members to share live positions without GPS and allows…

Continue Reading

ThursdaySep 10, 2026 10:00 am

NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (“MS”) following U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application. Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (“PAD2”) designed to target demyelination directly rather than suppress the immune system. The editorial also highlights Quantum BioPharma research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as…

Continue Reading